Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 26;14:538404. doi: 10.3389/fnins.2020.538404

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Rathore, Arora, Rastogi, Akhtar, Singh and Samim.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Photograph (40×) shows immunohistochemical expression of caspase-3 in the middle cerebral artery occlusion (MCAO) model in control (C), ischemic (I), and treatment groups of nanosilymarin doses NS1 (10 μg/kg b.wt), NS2 (100 μg/kg b.wt), NS3 (1,000 μg/kg b.wt), and free silymarin (Sil) (100 mg/kg b.wt). The control (C) group shows almost no expression for the caspase-3 marker, whereas the ischemic (I) group shows maximum expression. Treatments NS1 and NS2 showed moderate to mild expression but less than free silymarin; NS3 showed minimum expression. (B) Quantification of caspase-3 expression intensity as optical density (OD). The experiment was conducted for n = 3 data sets, and results are shown as mean ± SEM. Results on comparison with the control group showed a significant difference (^###p < 0.001). Results obtained showed significant difference from the ischemic group (^∗∗∗p < 0.001 and ^∗p < 0.05).